Tovaxin ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	3

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00595920 (ClinicalTrials.gov)	November 2007	3/1/2008	Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis	An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00	Multiple Sclerosis, Relapsing-Remitting;Clinically Isolated Syndrome	Biological: Tovaxin	Opexa Therapeutics, Inc.	NULL	Terminated	N/A	N/A	All	116	Phase 2	United States
2	NCT00245622 (ClinicalTrials.gov)	May 2006	20/10/2005	Autologous T Cell Vaccine (TCV) for Multiple Sclerosis	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin in Subjects With CIS or RR-MS	Relapsing-Remitting Multiple Sclerosis	Biological: Tovaxin Autologous T cell vaccine;Biological: Placebo	Opexa Therapeutics, Inc.	NULL	Completed	18 Years	55 Years	Both	150	Phase 2	United States
3	NCT00587691 (ClinicalTrials.gov)	July 2002	21/12/2007	Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis	An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive	Biological: Tovaxin Autologous T Cell Vaccine	Opexa Therapeutics, Inc.	NULL	Completed	18 Years	65 Years	All	16	Phase 1/Phase 2	United States